blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1572181

EP1572181 - PHARMACEUTICAL COMPOSITION COMPRISING A BETA-3-ADRENOCEPTOR AGONIST AND A SEROTONIN AND/OR NOREPINEPHRINE REUPTAKE INHIBITOR AND THE USE OF SAID COMPOSITION FOR TREATING BLADDER DYSFUNCTION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.05.2009
Database last updated on 08.04.2026
Most recent event   Tooltip05.11.2010Lapse of the patent in a contracting state
New state(s): GR		published on 08.12.2010  [2010/49]
Applicant(s)For all designated states
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2005/37]
Inventor(s)01 / MEHLBURGER, Ludwig
Heckengasse 5
55411 BINGEN / DE
02 / MICHEL, Martin
Pieter de Hoochstraat 5c
NL-1071 ED AMSTERDAM / NL
03 / WIENRICH, Marion
Kreuzstr. 57
64331 WEITERSTADT / DE
04 / EBINGER, Ursula
11 Ashwood Trail
Boonton Township, NJ 07005 / US
 [2005/37]
Application number, filing date03778298.403.11.2003
[2005/37]
WO2003EP12225
Priority number, dateEP2002002654627.11.2002         Original published format: EP 02026546
[2005/37]
Filing languageDE
Procedural languageDE
PublicationType: A2 Application without search report
No.:WO2004047830
Date:10.06.2004
Language:DE
[2004/24]
Type: A2 Application without search report 
No.:EP1572181
Date:14.09.2005
Language:DE
The application published by WIPO in one of the EPO official languages on 10.06.2004 takes the place of the publication of the European patent application.
[2005/37]
Type: B1 Patent specification 
No.:EP1572181
Date:25.06.2008
Language:DE
[2008/26]
Search report(s)International search report - published on:EP19.08.2004
ClassificationIPC:A61K31/195, A61K31/216, A61K31/381, A61P13/10
[2007/51]
CPC:
A61K31/381 (EP,US); A61K31/215 (EP,KR,US); A61K31/17 (EP,US);
A61K31/18 (EP,US); A61K31/185 (EP,US); A61K31/19 (KR);
A61K31/192 (EP,KR,US); A61K31/335 (EP,US); A61K31/34 (EP,US);
A61K31/4025 (KR); A61K31/403 (EP,US); A61K31/41 (EP,US);
A61K31/4166 (EP,US); A61K31/4245 (EP,US); A61K31/426 (EP,US);
A61K31/433 (EP,US); A61K31/435 (EP,US); A61K31/4406 (EP,US);
A61K45/06 (EP,KR,US); A61P13/00 (EP); A61P13/02 (EP);
A61P13/10 (EP); A61P25/00 (EP); A61P43/00 (EP) (-)
C-Set:
A61K31/17, A61K2300/00 (US,EP);
A61K31/185, A61K2300/00 (US,EP);
A61K31/18, A61K2300/00 (US,EP);
A61K31/192, A61K2300/00 (US,EP);
A61K31/215, A61K2300/00 (US,EP);
A61K31/335, A61K2300/00 (US,EP);
A61K31/34, A61K2300/00 (US,EP);
A61K31/381, A61K2300/00 (US,EP);
A61K31/403, A61K2300/00 (US,EP);
A61K31/4166, A61K2300/00 (EP,US);
A61K31/41, A61K2300/00 (EP,US);
A61K31/4245, A61K2300/00 (EP,US);
A61K31/426, A61K2300/00 (US,EP);
A61K31/433, A61K2300/00 (US,EP);
A61K31/435, A61K2300/00 (US,EP);
A61K31/4406, A61K2300/00 (EP,US)
(-)
Former IPC [2005/37]A61K31/192, A61K31/215, A61P13/10
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2005/37]
Extension statesAL27.06.2005
LT27.06.2005
LV27.06.2005
MK27.06.2005
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNG AUS EINEM BETA-3-ADRENOZEPTOR-AGONISTEN UND EINEM SEROTONIN- UND/ODER NOREPINEPHRIN-REUPTAKE-INHIBITOR UND DEREN VERWENDUNG ZUR BEHANDLUNG VON BLASENFUNKTIONSSTOERUNGEN[2005/37]
English:PHARMACEUTICAL COMPOSITION COMPRISING A BETA-3-ADRENOCEPTOR AGONIST AND A SEROTONIN AND/OR NOREPINEPHRINE REUPTAKE INHIBITOR AND THE USE OF SAID COMPOSITION FOR TREATING BLADDER DYSFUNCTION[2005/37]
French:COMPOSITION PHARMACEUTIQUE CONTENANT UN AGONISTE BETA-3-ADRENORECEPTEUR ET UN INHIBITEUR DE RECAPTAGE DE LA SEROTONINE ET/OU DE LA NOREPINEPHRINE AINSI QUE L'UTILISATION DE CETTE COMPOSITION POUR LE TRAITEMENT DU DYSFONCTIONNEMENT DE LA VESSIE[2005/37]
Entry into regional phase27.06.2005National basic fee paid 
27.06.2005Designation fee(s) paid 
27.06.2005Examination fee paid 
Examination procedure11.06.2004Request for preliminary examination filed
International Preliminary Examining Authority: EP
27.06.2005Examination requested  [2005/37]
16.12.2005Amendment by applicant (claims and/or description)
03.07.2006Despatch of a communication from the examining division (Time limit: M06)
03.01.2007Reply to a communication from the examining division
28.11.2007Communication of intention to grant the patent
08.04.2008Fee for grant paid
08.04.2008Fee for publishing/printing paid
Divisional application(s)EP05027827.4  / EP1640000
Opposition(s)26.03.2009No opposition filed within time limit [2009/23]
Fees paidRenewal fee
30.11.2005Renewal fee patent year 03
30.11.2006Renewal fee patent year 04
30.11.2007Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY25.06.2008
CZ25.06.2008
DK25.06.2008
EE25.06.2008
FI25.06.2008
IE25.06.2008
NL25.06.2008
RO25.06.2008
SI25.06.2008
SK25.06.2008
TR25.06.2008
BG25.09.2008
SE25.09.2008
GR26.09.2008
LU03.11.2008
PT25.11.2008
BE30.11.2008
MC30.11.2008
HU26.12.2008
[2010/49]
Former [2010/37]CY25.06.2008
CZ25.06.2008
DK25.06.2008
EE25.06.2008
FI25.06.2008
IE25.06.2008
NL25.06.2008
RO25.06.2008
SI25.06.2008
SK25.06.2008
TR25.06.2008
BG25.09.2008
SE25.09.2008
LU03.11.2008
PT25.11.2008
BE30.11.2008
MC30.11.2008
HU26.12.2008
Former [2010/34]CY25.06.2008
CZ25.06.2008
DK25.06.2008
EE25.06.2008
FI25.06.2008
IE25.06.2008
NL25.06.2008
RO25.06.2008
SI25.06.2008
SK25.06.2008
BG25.09.2008
SE25.09.2008
LU03.11.2008
PT25.11.2008
BE30.11.2008
MC30.11.2008
HU26.12.2008
Former [2010/32]CZ25.06.2008
DK25.06.2008
EE25.06.2008
FI25.06.2008
IE25.06.2008
NL25.06.2008
RO25.06.2008
SI25.06.2008
SK25.06.2008
BG25.09.2008
SE25.09.2008
LU03.11.2008
PT25.11.2008
BE30.11.2008
MC30.11.2008
Former [2009/43]CZ25.06.2008
DK25.06.2008
EE25.06.2008
FI25.06.2008
IE25.06.2008
NL25.06.2008
RO25.06.2008
SI25.06.2008
SK25.06.2008
BG25.09.2008
SE25.09.2008
PT25.11.2008
BE30.11.2008
MC30.11.2008
Former [2009/29]CZ25.06.2008
DK25.06.2008
EE25.06.2008
FI25.06.2008
IE25.06.2008
NL25.06.2008
RO25.06.2008
SI25.06.2008
SK25.06.2008
BG25.09.2008
SE25.09.2008
PT25.11.2008
MC30.11.2008
Former [2009/23]CZ25.06.2008
DK25.06.2008
EE25.06.2008
FI25.06.2008
IE25.06.2008
NL25.06.2008
RO25.06.2008
SI25.06.2008
SK25.06.2008
BG25.09.2008
SE25.09.2008
PT25.11.2008
Former [2009/22]CZ25.06.2008
DK25.06.2008
EE25.06.2008
FI25.06.2008
NL25.06.2008
RO25.06.2008
SI25.06.2008
SK25.06.2008
SE25.09.2008
PT25.11.2008
Former [2009/20]CZ25.06.2008
DK25.06.2008
FI25.06.2008
NL25.06.2008
RO25.06.2008
SI25.06.2008
SK25.06.2008
SE25.09.2008
PT25.11.2008
Former [2009/14]CZ25.06.2008
FI25.06.2008
NL25.06.2008
RO25.06.2008
SI25.06.2008
SK25.06.2008
SE25.09.2008
PT25.11.2008
Former [2009/12]CZ25.06.2008
FI25.06.2008
NL25.06.2008
SI25.06.2008
SE25.09.2008
PT25.11.2008
Former [2009/07]FI25.06.2008
NL25.06.2008
SI25.06.2008
SE25.09.2008
Former [2009/01]FI25.06.2008
NL25.06.2008
SI25.06.2008
Former [2008/50]FI25.06.2008
SI25.06.2008
Former [2008/48]SI25.06.2008
Cited inInternational search[Y]   THOR K B ET AL: "EFFECTS OF DULOXETINE, A COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR, ON CENTRAL NEURON CONTROL OF LOWER URINARY TRACT FUNCTION IN THE CHLORALOSE-ANESTHETIZED FEMAL CAT", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 274, no. 2, 1995, pages 1014 - 1024, XP009023623, ISSN: 0022-3565
 [Y]   SHARMA A ET AL: "PHARMACOKINETICS AND SAFETY OF DULOXETINE, A DUAL-SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR", JOURNAL OF CLINICAL PHARMACOLOGY, LIPPINCOTT CO, HAGERSTOWN, MD, US, vol. 40, no. 2, February 2000 (2000-02-01), pages 161 - 167, XP000904872, ISSN: 0091-2700

DOI:   http://dx.doi.org/10.1177/00912700022008810
 [Y]   SALETU B ET AL: "TANDAMINE - A NEW NOREPINEPHRINE REUPTAKE INHIBITOR CLINICAL, PSYCHOMETRIC AND QUANTITATIVE EEG STUDIES IN DEPRESSED PATIENTS", INTERNATIONAL PHARMACOPSYCHIATRY, KARGER, BASEL, CH, vol. 12, no. 3, 1977, pages 137 - 152, XP000605654, ISSN: 0020-8272
 [DA]   YAMANISHI TOMONORI ET AL: "The role of beta(3)-adrenoceptors in mediating relaxation of porcine detrusor muscle.", BRITISH JOURNAL OF PHARMACOLOGY. ENGLAND JAN 2002, vol. 135, no. 1, January 2002 (2002-01-01), pages 129 - 134, XP002272188, ISSN: 0007-1188

DOI:   http://dx.doi.org/10.1038/sj.bjp.0704470
 [A]   ANDERSSON K-E: "THE OVERACTIVE BLADDER: PHARMACOLOGIC BASIS OF DRUG TREATMENT", UROLOGY, BELLE MEAD, NJ, US, vol. 50, no. 6, SUPPL 1, 1997, pages 74 - 84, XP001189072, ISSN: 0090-4295 [A] 1-17 * abstract * * page 129, column R, paragraph 1 * * page 134, column L, paragraph 1 - column R, paragraph 1 *

DOI:   http://dx.doi.org/10.1016/S0090-4295(97)00595-5
 [A]   SELLERS DONNA J ET AL: "Potential therapeutic targets for treatment of the overactive bladder", WORLD JOURNAL OF UROLOGY, SPRINGER INTERNATIONAL, DE, vol. 19, no. 5, 2001, pages 307 - 311, XP002971377, ISSN: 0724-4983 [A] 1-17 * page 78, column R, paragraph L - page 79, column L, paragraph 3 *
 [A]   SPRINGER J P ET AL: "FACILITATORY AND INHIBITORY EFFECTS OF SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS ON HYPOGASTRIC NERVE-EVOKED URETHRAL CONTRACTIONS IN THE CAT: A PROMINENT ROLE OF URETHRAL BETA-ADRENERGIC RECEPTORS", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 152, no. 2, PART 1, August 1994 (1994-08-01), pages 515 - 519, XP008020464, ISSN: 0022-5347
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.